Nova Eye Medical
Nova Eye Medical is a medical device company focused on developing and commercializing innovative technologies for the treatment of glaucoma. Their proprietary technologies, including the iTrack™ family of canaloplasty devices and the Molteno3® glaucoma drainage device, offer comprehensive treatment options for ophthalmologists. The company collaborates with surgeons and researchers to develop solutions that address unmet needs in glaucoma management.
Short position
Nova Eye Medical (ASX:EYE) has 0.01% of its shares on issue reported as short positions as of 2 Oct 2026, or about 28,623 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.17% in January 2025. EYE is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Nova Eye Medical (EYE) short interest history
EYE Short Interest History
- 30-day change
- -0.00pp
- 90-day change
- -0.00pp
- 1-year change
- +0.00pp
- All-time high
- 0.17% (January 2025)
- All-time low
- 0.01% (July 2020)
Is EYE heavily shorted?
Not especially: 0.01% short interest is modest by ASX standards, ranking #588 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has EYE's short interest changed recently?
Over the past 30 days Nova Eye Medical's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.01% of shares on issue.
What is the highest EYE's short interest has been?
Since 2020, Nova Eye Medical's short interest peaked at 0.17% in January 2025 and bottomed at 0.01% in July 2020.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2020. See our methodology.